TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05074615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranio-Cervical Flexion Training
Description: Participants of this group will receive conventional training along with Cranio-cervical flexion training:~* The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks
Study: NCT06232629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TUS Active
Description: Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TUS Sham
Description: Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa
Study: NCT06388941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: LNP023 administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Standard of care
Study: NCT06025019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-based Electronic Health intervention
Description: The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes).
Study: NCT05162144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Medial Gastrocnemius Recession
Description: Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
Study: NCT05390099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moringa oleifera leaf
Description: Moringa toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf
Description: Moringa toothpaste
Study: NCT04800016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Vivity Extended Vision IOL
Description: UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
Study: NCT05718817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 capsules
Study: NCT05719584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypopressive exercises
Description: patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
Study: NCT04085887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinpoint-IR9000 endoscopic/handheld device
Description: Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinpoint-IR9000 endoscopic/handheld device
Description: Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinpoint-IR9000 endoscopic/handheld device
Description: Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).
Study: NCT01443117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV-23 Vaccine
Description: Administered as a 0.5 mL IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV-23 Vaccine
Description: Administered as a 0.5 mL IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-13 Vaccine
Description: Administered as a 0.5 mL IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-13 Vaccine
Description: Administered as a 0.5 mL IM dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Administered as a 0.5 mL IM dose
Study: NCT06369922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control TENS
Description: This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.
Study: NCT04714450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: MMST+
Description: The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
Study: NCT05478044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Ascorbic acid IV ampoules (20%).
Study: NCT06055114

Intervention type: DIAGNOSTIC_TEST
Intervention: Microscopic examination of vaginal discharge
Description: Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microscopic examination of vaginal discharge
Description: Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
Study: NCT06178822

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention
Study: NCT05478044

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline (0.9%)
Study: NCT06463158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Family Room App
Description: The Family Room is a dynamic, point of care tool. It guides families on how best to contribute to patient care by providing real time education, a sense of connection, emotional support, and resources that enable meaningful caregiving. Importantly, family caregivers receive virtual training on comfort-focused care activities that can be done at the bedside, as well as a mechanism within the electronic health record (EHR) to measure and record the effectiveness of the care they provide.
Study: NCT05980832

Intervention type: OTHER
Group type: OTHER
Intervention: Peer practitioner training - Peer Education Supported Psychosocial Skills Education
Description: Psychosocial skills training-practitioner training will be given to 4 patients diagnosed with chronic mental disorder by the research psychiatry nurse.~Educational content~1. Getting acquainted - briefing about the study~2. The Importance, Aims and Objectives of Psychosocial Skills Education~3. The importance of peer support~4. The importance, aims and objectives of peer education supported psychosocial skills training~5. Management of the meeting game, warm-up games and role plays~6. 1st and 2nd session peer education supported psychosocial skills training~7. 3rd and 4th session peer education supported psychosocial skills training~8. The last 5th and 6th sessions of peer education are supported by psychosocial skills training.~9. Key points and termination in group management. The training will be planned to last 10-13 hours in total. Trainer's booklet prepared by the researcher psychiatric nurse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Education Supported Psychosocial Skills Education
Description: It is a psychosocial skills training that will be given to both experimental groups in 6 sessions within 6 weeks. 2 of the 4 peer trainers who received the practitioner training will conduct the training. During the training period, the research psychiatric nurse will support.~Session titles are as follows:~1. Session:Preparation Session~2. Session: Understanding Mental Disorders~3. Session: Developing Communication Skills~4. Session: Developing Emotion Recognition and Expression Skills~5. Session: Dealing with Daily Living Activities and Problems~6. Session: Understanding the Stigma Experience~The duration of each session is determined as 90 minutes. Taking into account the patient's opinions breaks not exceeding 15 minutes will be given as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Education Supported Psychosocial Skills Education
Description: It is a psychosocial skills training that will be given to both experimental groups in 6 sessions within 6 weeks. 2 of the 4 peer trainers who received the practitioner training will conduct the training. During the training period, the research psychiatric nurse will support.~Session titles are as follows:~1. Session:Preparation Session~2. Session: Understanding Mental Disorders~3. Session: Developing Communication Skills~4. Session: Developing Emotion Recognition and Expression Skills~5. Session: Dealing with Daily Living Activities and Problems~6. Session: Understanding the Stigma Experience~The duration of each session is determined as 90 minutes. Taking into account the patient's opinions breaks not exceeding 15 minutes will be given as needed.
Study: NCT05171764

Intervention type: DEVICE
Intervention: Additional Gemstone Spectral Imaging (GSI) cardiac scan
Description: After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
Study: NCT04085887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinpoint-IR9000 endoscopic/handheld device
Description: Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Air camera
Description: Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Air camera
Description: Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Air camera
Description: Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Air camera
Description: Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDE-NEO-II
Description: Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).
Study: NCT06357819

Intervention type: DEVICE
Intervention: INSTI HCV Self Test
Description: Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
Study: NCT04085887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDE-NEO-II
Description: Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDE-NEO-II
Description: Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDE-NEO-II
Description: Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo).
Study: NCT05376111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, Azacitidine
Description: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
Study: NCT05130164

Intervention type: RADIATION
Intervention: CBCT
Description: Cone beam computed tomographic images selected for age estimation
Study: NCT04842604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: 25 mg or 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 100 mg/vial powder for 25 mg/mL suspension for injection
Study: NCT04445493

Intervention type: DEVICE
Intervention: MindRhythm Harmony
Description: Passive recording of the head pulse
Study: NCT05075148

Intervention type: OTHER
Intervention: radiology
Description: Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)